Helicobacter pylori eradication by low‐dose rifabutin triple therapy (RHB‐105) is unaffected by high body mass index

Abstract

Helicobacter pylori infection affects ~35% of Americans and may lead to serious sequelae if left untreated, including gastric cancer. Obesity is a significant risk factor for antibiotic treatment failure; however, little work has been done to understand the influence of high body mass index (BMI) on the success rates of H pylori eradication regimens in treatment‐naïve and refractory adult patients.